Table III.
Inhibitor and Concentration | Site of Action and Reference | Fluorescence Movement |
---|---|---|
mm | ||
Control (+N; 100 μm) | – | 9.0 ± 0.4 |
Bafilomycin A1 (0.3 μm) | Vacuolar H+-ATPase (Scott and Allen, 1999) | 8.2 ± 0.8 |
Cyclosporine A (0.3 μm) | ABCB transporters (p-glycoproteins; Loyola-Vargas et al., 2007) | 9.9 ± 1.0 |
Glybenclamide (10 μm) | ABCC transporters (MRP proteins; Forestier et al., 2003) | 7.6 ± 0.4a |
GSH (250 μm) | Redox (Espunya et al., 2006) | 5.6 ± 0.2a |
GSSG (250 μm) | Redox (Espunya et al., 2006) | 7.5 ± 0.4a |
Sodium o-vanadate (100 μm) | ABC transporters (Loyola-Vargas et al., 2007) | 8.0 ± 0.5 |
NPAb (10 μm) | Auxin transport (Jacobs and Rubery, 1988) | 9.3 ± 0.6 |
Nigericin (50 nm) | Membrane potentials (Casolo et al., 2003) | 9.9 ± 2.0 |
Valinomycin (1 μm) | Membrane potentials (Casolo et al., 2003) | 7.3 ± 0.6 |
Verapamil (100 μm) | ABCB transporters (p-glycoproteins; Loyola-Vargas et al., 2007) | 10.8 ± 2.0 |
Statistical analyses compared to control; tested with equal or unequal variance two-tailed Student's t tests depending on F test for variance; P < 0.05, n ≥ 6 replicates.
NPA, 1-N-naphthylphthalamic acid.